Standard versus Prolonged Neoadjuvant (Conversion) Chemotherapy to prolong survival of patients with Borderline and Locally Advanced Pancreatic Cancer: a phase III randomized controlled trial; ADVANTAGE

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502117-29-00

Enrollment

754

Registered

2023-02-20

Start date

2023-10-19

Completion date

Unknown

Last updated

2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced pancreatic cancer

Brief summary

• Overall survival at 24 months after randomization • Overall survival among resected patients at 24 months after randomization

Detailed description

• Overall survival in intention-to-treat and per protocol treated • Progression-free survival • Overall survival among non-resected at 24 months • Overall survival among patients with BR in the two arms and among patients with LAPC in the two arms in ITT • Overall and progression-free survival among resected patients with BR in the two arms and among resected patients with LAPC in the two arms • Difference in overall and progression-free survival between BR and LAPC patients – in ITT among al

Interventions

DRUGKalciumfolinat STADA 10 mg/ml injektionsvätska

DRUGlösning

DRUGGemcitabine Accord 100 mg/ml Koncentrat till infusionsvätska

DRUGOxaliplatin Hospira 5 mg/ml concentrate for solution for infusion

DRUGFluorouracil 50mg/ml Injection.

DRUGIrinotecan Hydrochloride 20 mg/ml concentrate for solution for infusion

DRUGPaclitaxel 6 mg/ml concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
• Overall survival at 24 months after randomization • Overall survival among resected patients at 24 months after randomization	—

Secondary

Measure	Time frame
• Overall survival in intention-to-treat and per protocol treated • Progression-free survival • Overall survival among non-resected at 24 months • Overall survival among patients with BR in the two arms and among patients with LAPC in the two arms in ITT • Overall and progression-free survival among resected patients with BR in the two arms and among resected patients with LAPC in the two arms • Difference in overall and progression-free survival between BR and LAPC patients – in ITT among al	—

Measure

Time frame

—

Countries

Germany, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026